Singapore markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.10+0.15 (+1.89%)
At close: 04:00PM EDT
7.75 -0.35 (-4.32%)
After hours: 06:34PM EDT

Vir Biotechnology, Inc.

1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees587

Key executives

NameTitlePayExercisedYear born
Dr. Klaus Frueh Ph.D.Co-Founder & Scientific Advisor177.66kN/A1960
Dr. Lawrence Corey M.D.Co-Founder & Scientific AdvisorN/AN/A1948
Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorN/AN/AN/A
Dr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerN/AN/AN/A
Ms. Heather Rowe ArmstrongVice President of Investor RelationsN/AN/AN/A
Ms. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryN/AN/AN/A
Cara MillerVice President of Corporate CommunicationsN/AN/AN/A
Dr. Jenny Gumm Ed.D., M.B.A.Executive VP & Chief Human Resources OfficerN/AN/AN/A
Dr. Antonio Lanzavecchia M.D., Ph.D.SVP & Senior Research FellowN/AN/AN/A
Dr. Lynne Krummen Ph.D.Executive Vice President of Regulatory & Program LeadershipN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Corporate governance

Vir Biotechnology, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.